Drug Sponsors

Teva names Oberman as CEO of Teva Americas Generics

Wednesday, November 7, 2012 12:14 PM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has made changes to its executive leadership team.

More... »


Takeda to acquire Envoy Therapeutics

Wednesday, November 7, 2012 11:24 AM

Takeda America Holdings, a subsidiary of Japanese, research-based company Takeda Pharmaceutical, has agreed to acquire Envoy Therapeutics, a privately-held drug discovery company based in Jupiter, Fla. Takeda's corporate venture arm, Takeda Ventures, participated in Envoy's series A financing in October 2009.

More... »


Ambit completes $25M financing for AML drug

Wednesday, November 7, 2012 10:36 AM

Ambit Biosciences, a privately held biopharmaceutical company based in San Diego, has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib, for the treatment of acute myeloid leukemia (AML).

More... »

SAFC to support next-gen NSAID product development

Monday, November 5, 2012 11:16 AM

Sigma-Aldrich’s custom manufacturing and services business unit, SAFC, has signed an agreement with South Korea-based CrystalGenomics, a clinical stage biopharmaceutical company, to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID).

More... »

Ziarco founded with Series A financing

Monday, November 5, 2012 11:01 AM

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

More... »

Icon reports Q3 revenue of $286M

Monday, November 5, 2012 09:24 AM

Icon, a global provider of outsourced development services, reported its financial results for the third quarter ended September 30, 2012. Net revenues for the quarter grew 19% to $286 million compared to $241 million in the same quarter last year.

More... »

Bayer HealthCare strengthens position in Russia

Friday, November 2, 2012 02:21 PM

Bayer HealthCare and Russian drug manufacturer Medsintez have entered into a strategic partnership to jointly manufacture and commercialize diagnostic imaging products as well as pharmaceuticals to treat infections and neural disorders.

More... »

Lilly to expand Indianapolis insulin manufacturing operations

Friday, November 2, 2012 10:38 AM

Global pharmaceutical company Eli Lilly announced a $140 million expansion to the company's Indianapolis insulin manufacturing operations. The 80,000-square-foot expansion, which will enable the manufacturing of insulin cartridges to meet the growing diabetes demand in the U.S., represents one of the most significant investments in Lilly's U.S.-based manufacturing operations in the past decade.

More... »

Thesan Pharmaceuticals closes $16M Series A funding

Wednesday, October 31, 2012 02:04 PM

Thesan Pharmaceuticals, a newly-formed biotech focused on dermatological conditions, has closed a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds. 

More... »

Novartis to build $500M biotech facility in Singapore

Wednesday, October 31, 2012 01:38 PM

Novartis has decided to construct a new state-of-the-art biotechnology production site in Singapore with an investment valued at over $500 million.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs